LLY
Eli Lilly and Company
LLY has the edge over ORCL overall, supported by stronger fundamentals and lower modeled downside.
ORCL
Oracle Corporation
ORCL offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ORCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
ORCL's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ORCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $127 | — |
| Cheap | 19x | $119 | -6.8% |
| Current | 20x | $127 | — |
| Fair | 30x | $189 | +49% |
| Expensive | 39x | $247 | +94% |
Historical ranges are pointers, not guarantees.
ORCL has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ORCL on the outlook, with more favorable profitability expectations.
ORCL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for ORCL, but weaker profitability.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ORCL on earnings, with stronger typical year-over-year growth.
ORCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.53 | +34% |
| Q3 2026 | $6.38 | +48% |
| Q2 2026 | $5.83 | +34% |
| Q1 2026 | $5.57 | +31% |
| Q4 2025 | $5.32 | +30% |
| Q3 2025 | $4.32 | +11% |
| Q2 2025 | $4.34 | +17% |
| Q1 2025 | $4.26 | +12% |
| Q4 2024 | $4.09 | +13% |
ORCL's earnings per share have climbed steadily: $6.38 over the past year, up 48% from the year before, and higher year over year for 15 quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ORCL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ORCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.3B | +30% |
| Q2 2026 | $19.2B | +21% |
| Q1 2026 | $17.2B | +22% |
| Q4 2025 | $16.1B | +14% |
| Q3 2025 | $14.9B | +12% |
| Q2 2025 | $15.9B | +11% |
| Q1 2025 | $14.1B | +6.4% |
| Q4 2024 | $14.1B | +8.6% |
ORCL's revenue has grown year over year for 13 quarters in a row: $19.3B last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | +6.1 points |
| Q2 2026 | 32% | -0.2 points |
| Q1 2026 | 32% | +0.9 points |
| Q4 2025 | 29% | -0.6 points |
| Q3 2025 | 29% | -1.3 points |
| Q2 2025 | 32% | -0.7 points |
| Q1 2025 | 31% | +2.6 points |
| Q4 2024 | 30% | +2 points |
ORCL has the edge over LLY on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ORCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.4B | -$5B |
| Q2 2026 | -$1.9B | +$1.1B |
| Q1 2026 | -$11.5B | -16275% |
| Q4 2025 | -$10B | -$7.3B |
| Q3 2025 | -$362M | -107% |
| Q2 2025 | -$2.9B | -189% |
| Q1 2025 | $71M | -98% |
| Q4 2024 | -$2.7B | -$1.7B |
ORCL has burned cash in seven of the last eight quarters: −$28.7B over the past year, against −$5.9B the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ORCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ORCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +86M shares |
| 1 year | +3.1% | +91M shares |
| 3 years | +6.3% | +177M shares |
| 5 years | +4.9% | +139M shares |
| Available history | -9.9% | -331M shares |
ORCL has 3B diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $95M |
| Q2 2025 | $150M |
| Q1 2025 | $150M |
| Q4 2024 | $150M |
| Q3 2024 | $150M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ORCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.2x | Very low |
ORCL has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ORCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 23.0 | Neutral |
ORCL's weekly RSI is 42 (neutral) and its Stochastic is 23 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ORCL PE vs Technology Sector
| Metric | ORCL | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 28% below |
| PE % | 28 | 35 | 7 pts below |
ORCL has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ORCL on trend strength, trading above more of its moving averages.
ORCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $131.1 | 3.1% below |
| 20 week MA | $137.6 | 7.7% below |
| 50 week MA | $160.3 | 21% below |
| 100 week MA | $181.4 | 30% below |
| 200 week MA | $151.9 | 16% below |
ORCL is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ORCL on returns for 2026, with the stronger performance.
ORCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $53.5 | $65.0 | +22% |
| 2021 | $65.0 | $89.7 | +38% |
| 2022 | $89.7 | $80.9 | -9.9% |
| 2023 | $80.9 | $105.4 | +30% |
| 2024 | $105.4 | $169.0 | +60% |
| 2025 | $169.0 | $198.0 | +17% |
| 2026 YTD | $198.0 | $127.1 | -36% |
ORCL is down 36% so far in 2026, after finishing higher in five of the previous six years.